Gene expression
Are there molecular subtypes of Alzheimer brains?
Open access · cc by · source: Europe PMC
Brain multi-omics integration found four multimodal AD profiles, including severe Knight-C4 with worse cognition and heavy molecular dysregulation.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Brain multi-omics reveals multimodal AD molecular profiles including a severe cluster.
Integrating transcriptomic/proteomic/metabolomic/lipidomic brain data yielded four multimodal profiles, including Knight-C4 with pronounced dysregulation and worse clinical features.
Evidence for the claim as stated.
Specialty clinics are delivering lecanemab with real-world workflow constraints.
A specialty memory-clinic report on lecanemab treatment adds practice-level evidence beside biomarker/pathology marker papers.
Scope note — molecular subtypes ≠ treatment eligibility/outcomes
Limits the claim's scope: a different population, assay, or outcome.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as supporting evidence on Alzheimer’s and MCI markers
Integrating transcriptomic/proteomic/metabolomic/lipidomic brain data yielded four multimodal profiles, including Knight-C4 with pronounced dysregulation and worse clinical features.
Placed as a scope qualifier on Alzheimer’s and MCI markers
A specialty memory-clinic report on lecanemab treatment adds practice-level evidence beside biomarker/pathology marker papers.
Placed as supporting evidence on Alzheimer’s and MCI markers
Integrating transcriptomic/proteomic/metabolomic/lipidomic brain data yielded four multimodal profiles, including Knight-C4 with pronounced dysregulation and worse clinical features.
Placed as a scope qualifier on Alzheimer’s and MCI markers
A specialty memory-clinic report on lecanemab treatment adds practice-level evidence beside biomarker/pathology marker papers.
Study at a glance
- Design
- Computational / modelling — Multi-cohort brain multi-omics ML clustering of AD molecular profiles
- N
- N=42 · Knight-C4 high-dysregulation cluster n=42 within four multimodal profiles
- Population
- Human AD brain cohorts with multi-omic + clinical/neuropath data
- Outcome
- Multimodal molecular clusters linked to cognition and progression
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Are there molecular subtypes of Alzheimer brains?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Four multimodal profiles.
We discovered 4 unique multimodal molecular profiles, one of them showing signs of poor cognitive function, a faster pace of disease progression, shorter survival with the disease, severe neurodegeneration and astrogliosis, and reduced levels of metabolomic profiles.
Knight-C4 n=42.
We identified 4 clusters ( Fig 2A ) in which the molecular profiles of Cluster4 (named Knight-C4 hereafter, n = 42) exhibited a pronounced dysregulation of genes, proteins, and metabolites.
Key findings
Four profiles emerged; one severe profile had poor cognition, faster progression, shorter survival, neurodegeneration/astrogliosis, and reduced metabolomic signals. Knight-C4 (n=42) showed pronounced multi-layer dysregulation.
Methodology
Integrated transcriptomic, proteomic, metabolomic, and lipidomic profiles with clinical/neuropathological data using machine learning and clustered multimodal profiles.
Limitations
Clusters are observational patterns, not proven treatment-response groups.
Related papers in this topic
Same topic cluster — not a recommendation engine.